Clinical trial
A Phase I, Randomized, Cross-over, Single-Center, Single Dose Fasted Study of EG-101 IV Injection (EG-ZNMP-01) in Healthy Volunteers to Serve as a Safety Lead-In for Dosing in Pregnant Women With Severe Pre-eclampsia
NCT07327255 is registered in ClinicalTrials.gov with Evergreen Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I, Randomized, Cross-over, Single-Center, Single Dose Fasted Study of EG-101 IV Injection (EG-ZNMP-01) in Healthy Volunteers to Serve as a Safety Lead-In for Dosing in Pregnant Women With Severe Pre-eclampsia
- Lead sponsor
- Evergreen Therapeutics, Inc.
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- June 30, 2026
- Completion date
- March 31, 2027
- Enrollment
- 24 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.